Form 10-Q · Quarterly report
Qnity Electronics 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0002058873
- Accession no.
- 0002058873-26-000043
Summary
Qnity Electronics reported third-quarter 2026 net sales of $1.56 billion, up 22% from $1.28 billion a year earlier on a 22% volume increase, with Interconnect Solutions up 30% and Semiconductor Technologies up 16%. The company also repriced its senior secured term loan facility on July 1, 2026, cutting the applicable margin to 1.75% from 2.00%, a change it expects to reduce annual cash interest expense by about $6 million.
Key points
- Net sales for the nine months ended September 30, 2026 were $4.3 billion, up 21% from $3.6 billion a year earlier, again driven by volume.
- About $1.98 billion of term loan principal was rolled over in the repricing and roughly $360 million was repaid and subsequently reissued, producing a $3 million loss on extinguishment in the third quarter.
- Under a $500 million share repurchase authorization approved by its board on February 20, 2026, the company repurchased $75 million of stock in the first nine months of 2026, leaving $425 million available.
- The company said its local-for-local sourcing of raw materials limits, but may not fully offset, exposure to tariff and trade-related risks.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION OVERVIEW We are one of the largest global leaders in materials and solutions for the semiconductor and electronics industries. We empower our customers’ technology roadmaps to enable advancements in megatrends such as artificial intelligence ("AI"), high-performance computing and advanced connectivity. We partner with leading semiconductor and advanced device manufacturers to address complex challenges and develop solutions that facilitate next-generation technological innovations. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.